tbuckley/cabot-search huggingface dataset:
Abstract 2243: Alterations in the binding of Meis proteins to HoxB13 or to DNA promote prostate cancer progression
Authors: Hannah J. Brechka, Masis Isikbay, Raj Bhanvadia, Donald Vander Griend
Journal: Cancer Research (2015)

Abstract Intro: One of the first germline mutations shown to confer an increased risk of early-onset prostate cancer (PrCa) is found in the Meis-binding domain of Homeobox B13 (HoxB13). Neither the function of this mutation nor the role of Meis proteins in PrCa has been elucidated. Meis proteins normally function as Hox gene cofactors, and regulate proliferation and cell fate. We hypothesize that disruption in normal Meis binding, either to transcriptional cofactors or DNA elements, is sufficient to alter gene transcription and increase progression of PrCa. Methods: Meis1/2 expression was used to stratify outcomes of men with Gleason 6/7 tumors in a retrospective bioinformatics analysis. Meis1/2 mRNA expression in cell lines was determined by qRT-PCR, and isoform distribution determined by TA-TOPO cloning. Cell number over time was determined for lines stably overexpressing Meis2E or A as compared to GFP in LNCaP and CWR-22Rv1. Results: We found that men diagnosed with intermediate Gleason scores and low expression of Meis had a worse prognosis than men with high levels of Meis. We found lower Meis mRNA expression in PrCa cell lines as compared to normal prostate epithelial cells. We determined that a variety of Meis2 isoforms are expressed in both cancer and normal, and the aggressive PrCa cell line CWR22Rv1 had a higher level of Meis2 isoforms with abrogated DNA-binding homeodomains. LNCaP cells overexpressing Meis2A showed significantly lower cell number over five days than GFP or Meis2E expressing cells. Conclusions: Full length Meis proteins may act as tumor suppressors while the homeodomain-less isoforms may act as oncogenes in the context of PrCa. This is innovative because we are the first to look at the role of Meis proteins in PrCa, and significant because it's linked to evidence involving mutations in HoxB13. Citation Format: Hannah J. Brechka, Masis Isikbay, Raj Bhanvadia, Donald Vander Griend. Alterations in the binding of Meis proteins to HoxB13 or to DNA promote prostate cancer progression. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2243. doi:10.1158/1538-7445.AM2015-2243
Thimerosal Provision Repealed
Authors: Brian Vastag
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
RSR13, a Synthetic Allosteric Modifier of Hemoglobin, Improves Myocardial Recovery Following Hypothermic Cardiopulmonary Bypass
Authors: Kenneth S. Kilgore, Charles F. Shwartz, Marsha A. Gallagher, Robert P. Steffen, Ralph S. Mosca, Steven F. Bolling
Journal: Circulation (1999)

Background —During hypothermic blood cardioplegia, oxygen delivery to myocytes is minimal with ineffective anaerobic metabolism predominating. RSR13, 2-[4-[[(3,5-dimethylanilino) carbonyl]methyl]phenoxy]-2-methylpropionic acid, a synthetic allosteric modifier of hemoglobin (Hb), increases release of oxygen from Hb, increasing oxygen availability to hypoxic tissues, and reverses the hypothermia-dependent increase in Hb oxygen affinity. We studied recovery of myocardial mechanical and metabolic function and examined myocardial morphology after cardioplegia, comparing RSR13 (1.75 mmol/L)-supplemented blood (RSR13-BC) to standard blood cardioplegia (BC). Methods and Results —Twelve dogs underwent 15 minutes of 37°C global ischemia on cardiopulmonary bypass, followed by 75 minutes of hypothermic cardioplegia (13°C) with either BC (n=6) or RSR13-BC (n=6). There were no differences in baseline function between groups. Cardiac function was assessed after 30 minutes of 37°C reperfusion (BC versus RSR13-BC, respectively) by measuring: % return to normal sinus rhythm (0/100%), % of baseline+dP/dt (33.7±1.7/76.3±1.9), % of baseline−dP/dt (26.6±2.0/81.1±1.6), stroke volume (3.5±0.5/7.1±0.9 mL), cardiac output (340±20/880±40.3 mL/min), and LVEDP (11.3±2.2/0.3±2.9 mm Hg). Postischemic oxidative and metabolic parameters including myocardial lactate, pyruvate, ATP content, and percent water content also were determined. Histological analysis demonstrated preservation of endothelial and myocyte morphology in hearts receiving RSR13-BC compared with BC. Conclusions —These results indicate that in the setting of hypothermic cardiopulmonary bypass, RSR13 improves recovery of myocardial mechanical and metabolic function compared with standard hypothermic BC. Findings from this study suggest that RSR13-BC, by decreasing hemoglobin oxygen affinity, improves oxidative metabolism and preserves cellular morphology, resulting in significantly improved contractile recovery on reperfusion.
THE DISAPPEARING BONES: II
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Goodpasture's syndrome. Treatment failure with azathioprine
Authors: R. E. Holman
Journal: JAMA (1966)

Goodpasture's syndrome remains a disease of undetermined etiology although the possibility of an immunologic basis has been raised. Immunosuppressive agents have been used late in the course of this disease without benefit.<sup>1</sup>The purpose of this paper is to report the results of azathioprine (Imuran) therapy begun prior to the onset of renal insufficiency in a patient with classical Goodpasture's syndrome. <h3>Report of a Case</h3> This 20-year-old white man had been well until the first of Jan, 1965, when he suddenly began to cough bright red blood. He was admitted to another hospital where an x-ray film revealed pulmonary infiltrates (Fig 1). The hematocrit reading and analysis of the urine were reported as normal, but a value for blood urea nitrogen (BUN) was not determined. The patient improved spontaneously and after one week, the chest appeared normal on a radiograph. The patient had hemoptysis again on Feb 1, and
Evaluation of a New Antipsychotic Agent
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pancreatic Imaging
Authors: JERROLD A. VAN DYKE
Journal: Annals of Internal Medicine (1985)

Methods now available for evaluating the pancreas include computed tomography, ultrasound, angiography, endoscopic retrograde cholangiopancreatography, and percutaneous fine-needle aspiration. Computed tomography is best for initial evaluation of the patient with suspected pancreatic disorders as it is technically adequate and provides detailed anatomic information. Ultrasound also provides detailed information and survey capabilities but examinations are often technically unsatisfactory. Angiography, endoscopic retrograde cholangiopancreatography, and fine-needle aspiration provide important diagnostic information but are more invasive and require considerable operator skill. These techniques are secondary tests not indicated for the initial evaluation of every patient. No single test will always provide all necessary diagnostic information, and the appropriate utilization of each method requires an understanding of its strengths and weaknesses.
Correction
Journal: JAMA (1885)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cocaine Abuse
Authors: Elizabeth A. Warner
Journal: Annals of Internal Medicine (1993)

Purpose: To discuss the forms of cocaine that are available and their methods of administration and to review the medical complications of cocaine abuse. Data Sources: Pertinent articles were identified through a MEDLINE search of the English-language literature from 1986 to 1992 and through a manual search of bibliographies of all identified articles. Study Selection: All articles describing complications of cocaine use were either case reports, review articles, or small series. No controlled studies on the subject were available. Data Synthesis: A qualitative description of reported complications without the use of quantitative methods. Results: Multiple complications of cocaine use have been described and are often related to the method of administration of cocaine. Since the introduction of freebase and crack cocaine, new complications have been noted, and nearly all organ systems have been affected. Indirect complications, related to violent behavior and infectious diseases, are also important consequences of cocaine use. Conclusions: Adverse reactions to cocaine use should be considered in the differential diagnosis of various disorders, particularly ischemic events in young adults. The actual frequency of each complication is unknown.
?1-antichymotrypsin (?1AC) deficiency: HIgh prevalence in HCV-related cirrhosis and chronic active hepatitis (HCV) TD Schiano, F Kueppers, SV Bellary, YT Wachtfogel, RM Thomas, K Rothstein and M Black. Temple University School of Medicine. Depts. of Gastroenterology, Pulmonary and Pathology
Journal: Hepatology (1995)
P08.19 Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM)
Authors: M. van den Bent, H. K. Gan, A. B. Lassman, P. Kumthekar, N. Butowski, Z. Lwin, L. B. Nabors, J. Simes, K. Holen, D. A. Reardon
Journal: Neuro-Oncology (2016)

subtypes showed that M1 was enriched with neural subtype-specific genes.Using the gene expression data from four fetal neuronal stem cell lines and 15 GBM-derived neural stem (GNS) cell lines, we found that M1 was also enriched for genes that are up regulated in GNS.CONCLUSIONS: These results provide empirical support for a unique gene network influencing GBM invasive margins and illustrate how systemslevel analyses can reveal relationships between invasion-associated genes in GBM. P08.
Perspectives On The Discovery Of Central Monoaminergic Neurotransmission
Authors: A Carlsson
Journal: Annual Review of Neuroscience (1987)

The brain's default mode network consists of discrete, bilateral and symmetrical cortical areas, in the medial and lateral parietal, medial prefrontal, and medial and lateral temporal cortices of the human, nonhuman primate, cat, and rodent brains. Its ...Read More
Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex
Authors: K. Henry
Journal: JAMA (1988)

Zidovudine was present in the semen and serum of six patients with acquired immunodeficiency syndrome or the related complex who were receiving 200 mg of the drug orally every four to six hours. Mean semen zidovudine levels (as measured by a new radioimmunoassay) in samples collected 0.75 to 1.25 hours after oral dosing were 3.63 to 7.19 μmol/L. Levels in semen samples collected 3.0 to 4.5 hours after oral dosing were 1.68 to 6.43 μmol/L. These values are above the in vitro minimum inhibitory concentration for the human immunodeficiency virus type 1 (HIV-1). Mean serum concentrations at the early and late times after oral dosing were 0.22 to 3.07 μmol/L and 0.10 to 1.42 μmol/L, respectively. Ratios of semen/serum zidovudine levels ranged from 1.3 to 20.4. It is possible that a pH-dependent trapping mechanism, which has been described in the prostate for other antibiotics, was responsible for the relatively high semen levels observed. (<i>JAMA</i>1988;259:3023-3026)
Occupational disease and the kidney.
Journal: BMJ (1981)

Diatoms can appear in the tissues, both from ingestion and from inhalation, and non-drowned cadavers in Berlin have been found to contain marine diatoms.Monkeys from dry, dusty areas may have heavy diatom loads in their lungs.The wrappers of cheap cigars contain numerous diatoms introduced in processing, and these can survive the burning process to be inhaled or swallowed.Experimental work on animals shows that inhaled dust can appear in the tissues, an obvious access route for airborne diatoms.Perhaps the most striking finding of some German workers was that diatoms could be recovered from the tissues of stillborn and premature babies.Nevertheless, some forensic pathologists, notably in Belgium, where much pioneer work has been done, firmly believe in the reliability of the diatom test.Possibly the matter may be resolved by a quantitative measurement of diatom penetration.Meanwhile, the pathologist must continue to accept further frustration in trying to interpret the findingsor very often, the lack of findings-in many of his immersed bodies.
Contaminated aqueous benzalkonium chloride. An unnecessary hospital infection hazard
Authors: M. J. Frank
Journal: JAMA (1976)

During January and February 1975, nine patients on a single ward of a rural Tennessee hospital unexpectedly developed sepsis. The aseptic technique employed in the management of intravenous infusions was implicated.<i>Pseudomonas cepacia</i>was recovered from the following: bloodstream, inuse intravenous infusions, and the antiseptic, aqueous benzalkonium chloride. This outbreak again calls attention to the infection risk associated with the use of this product. Selection of less hazardous antiseptics and disinfectants is strongly recommended. (<i>JAMA</i>236:2418-2419, 1976)
Recurrent erythema multiforme and Herpes genitalis (type 2)
Authors: M. Britz
Journal: JAMA (1975)

IN 1972, MacDonald and Feiwel<sup>1</sup>cultured herpes simplex (HS) type 2 from the cutaneous bullae of a woman who had an erosive herpetic cervicitis, erythema multiforme (EM), and an elevated antibody titer to HS type 2. The purpose of this communication is to report what is, to our knowledge, the first case of recurring EM with mucous membrane involvement that was associated with culturally proved HS type 2 genital infection. Recognition of this clinical picture and familiarity with the diagnostic techniques of viral culture in these cases is imperative, as the incidence of EM associated with herpes is expected to parallel the rise in herpes genitalis.<sup>2</sup> <h3>Report of a Case</h3> A 17-year-old youth was admitted to the hospital in July 1973 complaining of photophobia, dysuria, and vesicoerosive lesions on the glans penis and coronal sulcus. On admission, he did not appear acutely ill. Examination disclosed erythematous papules and
Captopril in diuretic-treated hypertensive patients
Authors: H. Koffer
Journal: JAMA (1980)

Eight hypertensive patients with normal renal function and receiving diuretic therapy for at least 28 days received captopril in small increasing doses (6.25, 12.5, and 25 mg). Supine and standing blood pressure (BP) and pulse rate, plasma renin activity (PRA), and plasma aldosterone concentration (PAC) were measured before and after captopril administration. The mean (±SEM) maximal decline in BP was 38/18±3/2, 34/18±4/2, and 25/17±3/2 mm Hg and occurred within 70 minutes of each of the three doses. In contrast, the duration of a 10 mm Hg or greater decrease in BP was prolonged markedly (103±5, 175±15, and 287±10 minutes) after each dose increment. After captopril, mean PRA levels increased while PAC levels fell. Transient dizziness on standing occurred in two patients, but captopril was otherwise well tolerated. Evaluation of the response to initial doses of captopril appears to be helpful in predicting maintenance requirements. (<i>JAMA</i>1980;244:2532-2535)
Coagulation abnormalities in patients with Gaucher's disease: Effect of therapy
Authors: H.H. Billett, S. Rizvi, A. Sawitsky
Journal: American Journal of Hematology (1996)

Various coagulation defects have been associated with Gaucher's disease, including factor iX deficiency and acquired von Wiiiebrand's dlsease (VWD).We performed repeated coagulation assays in 9 patients with Gaucher's disease over a period of 2 years.The prothrombin time (PT) and fibrinogen levels were normal in 8 of 9 patients, while the partial thromboplastin time (PlT) was abnormal in 5 of 9; ail mixing PTT tests showed correction.Factor IX was normal repeatedly in the 7 of 7 patients tested.In contrast, factor XI was decreased in 3 of 9 patients assayed.Anticardioiipin (ACL) IgM was normal in ail patients.ACL IgG was highly variable; levels were abnormal at least once in 6 of 8 patients, but were also normal at least once in 7 of 8 patients.Factor Vlii was also quite variable: levels were decreased at least once in 4 of 9 patients, and normal at least once in 8 of 9 patients.Von Wiiiebrand factor antigen (VWF Ag) studies were normal in 7 of 8 patients, but VWF activity was decreased at least once in 4 of 8 patients.in some patients, these problems could be overcome by specimen dilution.in only 1 patient was VWF Ag decreased; this patient had a factor VlllC level of 13%. and VWF activity of 18.7%.Coaguiation assays performed before and after alglucerase administration failed to demonstrate any significant improvement in these assays, and neither was there a consistent Improve ment over the duration of therapy.We suggest that previously reported decreases in factor IX and VWF may be secondary to the interfering presence of increased cerebroside levels.Caution must be used in the interpretation of clotting assays in the patient with Gaucher's dlsease.
New uses for phenytoin
Authors: P. Walson
Journal: JAMA (1975)

PHENYTOIN (diphenylhydantoin) is a clinically accepted therapeutic agent for seizure control, for the treatment of cardiac arrhythmias, and in the diagnosis (and treatment) of certain endocrine diseases. In addition, however, phenytoin has been reported to be of value in treating at least 75 different symptoms and disorders. Bogoch and Dreyfus<sup>1</sup>have reported these various clinical uses in their book,<i>The Broad Range of Use of Diphenylhydantoin</i>. As pointed out in the<i>Medical Letter on Drugs and Therapeutics</i>, the book lists a total of 75 symptoms and disorders, from abdominal pain to wounds, in which phenytoin is reported to be valuable. The bibliography is of interest, but the reviews of the uses of the drug are too uncritical to be of much value. Of the 750 articles mentioned, only 17 studies are described as being controlled to any extent. The majority of these proposed uses are supported only by anecdotal evidence.